FDA Acceptance of Calcipotriene Supplement by Glenmark
The FDA has accepted the supplement application ANDA205772 for Calcipotriene submitted by Glenmark.
Asset / Drug
Drug and asset intelligence for Glenmark with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.